MatchTx is the first to market with a purpose built personalized medicine data solution that functions well where there are more data points than subjects (other predictive analytics methods for cancer fail when there are very large numbers of clinical and genetic data points impacting drug response). The product is a Software as a Service (SaaS) solution that enables clients to upload their own clinical and genomic data sets privately, augment their results with our enhanced public data sets, and dynamically get best matched recommendations for new patients based on their similarity to reference patients based on clinical, genetic, and outcomes data. Expert opinion is that FDA approval is not required to utilize MatchTx for clinical studies such as using its predictive clinical information as an additional guide to trial matching for patients, so there are no regulatory barriers for use. Furthermore, all patient data are de-identified (no PHI) so HIPAA is not an issue.
MatchTx provides its platform to biotech and Pharma companies, academic health centers, clinical CRO’s and biomedical research organizations that are developing and/or testing cancer drugs. For clinical trials, each patient that the MatchTx solution can exclude from a trial based on being a better match to non-responders saves the $26,000 cost of that patient, plus another $100,000 in additional patients needed to bring up the required response rate. Reassigning just 8 patients to other trials can save a Pharma company over $2 Million and minimize adverse events. For certain cancers there are specific marker combinations (cancer type, specific genetic markers) that correlate well to optimal treatment. For many others today, it is a trial and error system that ends poorly for many patients. MatchTx provides an adaptive learning software system that utilizes big biomedical data in a new way to improve outcomes for trials, identifies new biomarker patterns for development of personalized medicines, enables repositioning of failed drugs, and will ultimately enable personalized cancer treatment. MatchTx also helps guide drug development efforts by finding genetic targeting profiles. MatchTx has an addressable target market of 2000 clinical trials and 20,000 R&D projects today.
MatchTx provides its product as Software as a Service (SaaS) on licensed servers behind customers’ firewalls or hosted in the cloud. Either way, your data are secure and separate from other studies, and our clients always own and control their own data. We can also provide add-on professional services for additional data processing or customizing analyses and reporting to meet your needs. Our model is to lower barriers to engage quickly with our client partners and then work with you to grow projects from drug development and clinical research studies to clinical trials as best meets your organization’s needs. The MatchTx annual license fee ranges based on the size and complexity of your project and whether it is a research project or a clinical trial. We offer academic discounts and special pricing for pilot/proof of concept studies – please contact us for more information about how to partner.